GIST Specialist for Culver City, CA
Being told a gastrointestinal stromal tumor should be watched, or that it must come out, is only useful if someone explains the reasoning. Joshua Ellenhorn, MD, FACS reads the imaging and pathology himself and shows you the numbers the decision rests on.
- Second opinions on GIST risk grading and surveillance plans
- Clinical Professor of Surgery, Cedars-Sinai Medical Center
- Works alongside your existing medical oncologist
- Fifteen to twenty minutes north on La Cienega
Your GIST Has a Risk Grade. Ask What It Is.
Every gastrointestinal stromal tumor sits somewhere on a risk scale, and three variables put it there. How large it is. Where in the digestive tract it grew. And the mitotic index, which counts how many tumor cells were actively dividing in the specimen.
Those three numbers do an enormous amount of work. They determine whether a small tumor can be safely watched instead of removed. They determine whether you need three years of imatinib after surgery or none at all. They set how often you should be scanned and for how long. A two centimetre gastric tumor with a low mitotic count and a six centimetre small bowel tumor with a high one carry the same diagnosis and almost nothing else in common.
Which is why a recommendation without stated reasoning is worth questioning. Patients arrive here regularly having been told to watch something, or to have something removed, with no explanation of the grading behind it. Sometimes the original advice was right. Sometimes it was not. Either way you are entitled to see the reasoning.
Where GIST Comes From
GIST develops from the interstitial cells of Cajal, a network of pacemaker cells inside the wall of the digestive tract that coordinates the contractions moving food along. It is a sarcoma rather than a carcinoma, and it does not behave like the stomach or colon cancers most people picture.
Because it starts within the wall rather than on the lining, it tends to grow outward. That is why a GIST can reach a significant size without symptoms, and why an endoscopy may show nothing more than a smooth bulge under normal looking tissue.
Nearly all carry a mutation in KIT, a minority in PDGFRA. Those mutations jam a cellular growth switch permanently on. The same fault is the reason targeted tablets work against GIST when they do nothing for most sarcomas, and the specific mutation determines which drug and what dose.
How it tends to present
- No symptoms at all, found on imaging done for something else
- Iron deficiency anemia turning up on routine bloodwork
- Dark or tarry stools from slow bleeding into the bowel
- Early fullness, bloating, or a vague abdominal ache
- Nausea and vomiting if the tumor begins to obstruct
Getting the Numbers That Matter
A CT, a PET/CT, or an upper endoscopy usually finds a GIST. Size and location come from the imaging. The mitotic index comes only from tissue, which is one reason the biopsy question is not straightforward.
Sampling carries a genuine hazard: rupturing the tumor capsule can seed cells across the abdominal cavity and permanently change the outlook. Endoscopic ultrasound guided sampling is the controlled approach, and it also solves the problem that these tumors sit beneath the lining where a standard endoscope cannot reach. For some tumors the correct decision is to skip biopsy and proceed to resection, where the whole specimen yields a far more reliable count anyway.
Mutation testing belongs on the same specimen. KIT exon 11 tumors respond to standard dose imatinib. Exon 9 tumors frequently need higher dosing. PDGFRA and wild type tumors behave differently again. Starting therapy without that result is guesswork.
What Follows From the Grading
Risk grade does not just describe your tumor. It selects the treatment path.
Surveillance or Simple Resection
A small gastric tumor with a low mitotic count may be watched with periodic imaging, or removed with a wedge resection and nothing further. No medication, and a surveillance schedule that tapers rather than continuing indefinitely.
Surgery Plus Imatinib
Larger tumors, small bowel tumors, and high mitotic counts generally warrant complete resection followed by roughly three years of adjuvant imatinib to suppress recurrence. Mutation status determines whether standard dosing will be effective.
Drugs First, Then Surgery
Where disease has spread, usually to the liver, targeted therapy takes the lead and surgery becomes selective: resecting or ablating what remains once the drug has done its work. Sequencing here is where specialist judgment matters most.
The Surgery, Documented
Recordings of real GIST resections narrated by the surgeon who performed them. Useful for judging whether someone does this often rather than occasionally.
Laparoscopic Resection of a Gastric GIST
A gastric GIST removed through small incisions with the capsule kept intact.
Gastric GIST Resection: A Simplified Approach
A technique refined across many cases to shorten operating and recovery time.
Robotic Resection of a Duodenal GIST
Duodenal GIST is one of the harder locations. Robotic assistance permits removal while sparing the pancreas and bile duct.
Whole Tumors Give Better Numbers
A needle sample gives a partial picture of mitotic activity. The intact specimen gives the real one, which is part of why the surgical approach and the risk grading are not separate questions.
Credentials and Licensure
Two American Board of Surgery certifications, a teaching appointment at Cedars-Sinai, and membership of the societies that set the standards for this disease.
- American Board of Surgery, certified in General Surgery
- American Board of Surgery, certified in Colorectal Surgery
- California State Medical License
- Florida State Medical License
Joshua Ellenhorn, MD, FACS
Dr. Ellenhorn is a surgical oncologist and Clinical Professor of Surgery at Cedars-Sinai Medical Center, and a collaborative member of the Samuel Oschin Comprehensive Cancer Institute. He is regarded as one of the foremost GIST surgeons in the country.
His practice concentrates on complex abdominal cancers and gastrointestinal stromal tumors rather than covering general surgery broadly. That focus is why oncologists across Los Angeles and beyond send these cases to him specifically, and why the technical detail in his published operative videos is possible at all.
He is certified by the American Board of Surgery in General Surgery and Colorectal Surgery, a Fellow of the American College of Surgeons, and a member of the Society of Surgical Oncology and the American Society of Clinical Oncology. He practises with the Surgery Group of Los Angeles.
From Uncertainty to a Graded Plan
Send Everything
Call (310) 356-3792 or book online, then forward imaging, endoscopy reports, and the full pathology including the mitotic index and any mutation testing. The pathology report is the document that matters most here.
See the Reasoning
You should leave knowing your risk grade, the three numbers behind it, and what follows from it. If a previous recommendation is being changed, you will be told exactly why.
Treat and Monitor
Surgery where indicated, often laparoscopic and often a short stay, then a defined surveillance schedule. If adjuvant imatinib is warranted, your Culver City oncologist receives everything needed to start it.
What Patients Say
Reviews left by patients treated by Dr. Ellenhorn at the Surgery Group of Los Angeles.
★★★★★The staff at the Surgery Group of Los Angeles are wonderful. They are kind, very attentive, the office is clean and I did not have to wait long at all. I cannot say enough great things about Dr. Ellenhorn. He is an excellent surgeon who is highly skilled and very knowledgeable. I cannot thank him enough for all he has done for my family and I.
Erika Frank
★★★★★I was very pleased with the office staff, they were always very pleasant and helpful. I was very impressed with Dr. Ellenhorn as well. He was very friendly and addressed all my concerns regarding my surgery and aftercare and follow up.
Terry Jackson
Twenty Minutes North
From downtown Culver City, La Cienega north to 3rd Street is the straight line and usually the quickest. From the Hayden Tract or the studio lots on Washington, either Robertson or La Cienega north gets you there in much the same time. From the Fox Hills and Slauson side, allow a few extra minutes and use La Cienega.
The office sits in the medical plaza attached to Cedars-Sinai Medical Center, so imaging, pathology review, and surgery happen in one building rather than across three separate trips. Expect fifteen to twenty minutes from 90230 and 90232 outside of peak traffic.
Patients travelling from outside the region, including Arizona and Nevada, can have imaging and pathology reviewed remotely before deciding whether to travel.
8635 W 3rd St, Suite 880W
Los Angeles, CA 90048
Monday to Saturday, 11:00am to 8:00pm
Closed Sunday
Frequently Asked Questions
I was told to just watch my GIST. Should I get a second opinion?
What determines whether my GIST is high risk or low risk?
How is a mitotic index measured?
Do I need imatinib after surgery or not?
Can a GIST come back after it has been completely removed?
How far is your office from Culver City?
Will you coordinate with my oncologist near Culver City?
What happens if the pathology comes back different from expected?
Is GIST hereditary? Should my family be tested?
Ask What Your Risk Grade Is.
If you have a GIST diagnosis and nobody has explained the size, site, and mitotic index behind the plan, a specialist reading of your existing records is the most useful hour you can spend.
